Less than three months after linking up with Takeda Pharmaceutical Co. Ltd., the UK's Evox Therapeutics Ltd. has bagged another big pharma partner and signed a multi-target RNA interference (RNAi) and antisense pact looking at potential treatments for neurological disorders with Eli Lilly & Co..
UK's Evox Gets Lilly Onboard For CNS Exosome Collaboration
Banks $20m Up Front
The US major will work with Evox Therapeutics on potential treatments of neurological disorders using the Oxford-based firm's DeliverEX platform.
More from Neurological
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
More from Therapy Areas
• By
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
• By
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
• By
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.